Peptides by condition · Brain and nerves

Peptides studied for stroke

Checked against our study pages and the FDA labelsPublished by PepVault

Our library holds 7 study pages on stroke: 6 in people (4 of them meta-analyses or randomized trials), and 1 in animals. They studied 4 compounds, with this many study pages each: Cerebrolysin 4, HGH 1, Melanotan I 1 and NSI-189 1.

What the research on stroke looks like

Read the design before any result. Of these 7 studies, 1 was in animals and 6 were in people, the largest pooling 1,879 people. A finding in cells or animals is where research starts, and many such findings do not hold up in people.

An ischemic stroke happens when a blocked blood vessel cuts off part of the brain, and recovery depends on how much tissue survives and how well the brain rewires. The peptides studied after stroke were given to protect brain cells or to aid that recovery; the largest body of work is on Cerebrolysin, a mix of peptides made from pig brain.

Stroke trials score recovery on scales such as the NIHSS, a checklist of neurological deficits, and on tests of arm and hand movement, usually at about three months. Early trials check safety in the first days after the stroke.

Trials of the same compound have disagreed, so a pooled analysis and the largest single trial deserve the most weight. Stroke studies in rats block an artery for a set time, which differs from strokes in people.

Our study pages on stroke by design: Trials in people 4, Other in people 2, Animals 1, Cells 0, of 7.Trials in people4Other in people2Animals1Cells0
How many of the 7 study pages on this condition reach each design, strongest at the top: meta-analyses and randomized trials in people, other studies in people, animals, cells.

The 7 studies, by compound

Grouped by the compound each study is filed under, and within each, strongest design first. Each line gives the design, who was studied, how many and the year, before the finding.

  1. Cerebrolysin

    4 in people

    For stroke, 4 of our study pages are filed under Cerebrolysin: 1 meta-analysis, 2 randomized trials and 1 clinical trial in people. The largest in people pooled 1,879 people and was published in 2018. They were published from 2012 to 2025, in Neurol Sci, Stroke and Transl Stroke Res.

    Cerebrolysin has no FDA-approved product: Drugs@FDA lists no application for it.

  2. HGH

    1 in people

    For stroke, 1 of our study pages is filed under HGH: 1 randomized trial in people. It enrolled 60 people and was published in 2020, in J Comput Assist Tomogr.

    FDA-approved for other uses, not for stroke: Humatrope (injection) for growth failure in children who make too little growth hormone and several other causes of short stature, and growth hormone deficiency in adults.

  3. Melanotan I

    1 in people

    For stroke, 1 of our study pages is filed under Melanotan I: 1 clinical trial in people. It enrolled 6 people and was published in 2023, in BMC Neurol.

    FDA-approved for other uses, not for stroke: Scenesse (implant) for more pain-free time in light for adults who have had light reactions from erythropoietic protoporphyria (EPP), a rare inherited disease.

  4. NSI-189

    1 in animals

    For stroke, 1 of our study pages is filed under NSI-189: 1 animal study (rats). It was published in 2017, in J Cell Physiol.

    NSI-189 has no FDA-approved product: Drugs@FDA lists no application for it.

Side by side

For the 4 compounds on this page: studies in people, studies in animals or cells, the size of the largest study in people, and the FDA status from the labels our status pages read (a dash where they hold no record).

CompoundIn peopleAnimals or cellsLargest in peopleFDA
Cerebrolysin401,879Not approved
HGH1060Approved for other uses
Melanotan I106Approved for other uses
NSI-18901—Not approved

What the studies did not show

Each study page names its own limits. These are the questions still open, in the study pages’ words.

  • Cerebrolysin: better NIHSS scores after stroke across nine trialsThe main result covers early recovery, up to about a month; the 90-day disability result comes from a smaller group of 314 patients with moderate to severe stroke. Four of the pooled trials entered the analysis as aggregate data rather than individual patient data.
  • Melanotan I: well tolerated in 6 acute stroke patientsWith only 6 patients and no control group, the trial cannot show whether the improvement came from the drug or from natural recovery after stroke. The authors say randomized studies are needed to test the benefit.

This page is a reading of published studies, not medical advice. A diagnosis, and what to do about it, is a conversation with a clinician.

Questions

Which peptides have been studied for stroke?

Our 7 study pages on stroke are filed under 4 compounds, with this many each: Cerebrolysin 4, HGH 1, Melanotan I 1 and NSI-189 1. Cerebrolysin has the most.

Have any been tested in people with stroke?

Yes: 6 of the 7 were in people, 4 of them meta-analyses or randomized trials (Cerebrolysin and HGH). The largest pooled 1,879 people: “Cerebrolysin: better NIHSS scores after stroke across nine trials” (2018).

Is any peptide FDA-approved for stroke?

Not by the labels our status pages read: of the 4 compounds here with an FDA record, none has a use tied to stroke. HGH and Melanotan I are FDA-approved for other uses.

How large were the studies in people on stroke?

Of the 6 in people, 4 give their size on our pages: 2 had 1,000 people or more and 2 had fewer than 100. The largest, a meta-analysis from 2018, pooled 1,879.

What did the animal and cell studies on stroke use?

1 animal study (rats), filed under NSI-189. A result in animals or cells shows what to test next, not what happens in a person.

What is the newest study on stroke here?

Of our study pages on stroke, the newest is “Cerebrolysin after thrombectomy: 68% vs 44% independent at 90 days”, a clinical trial in people published in 2025.

How this page was built

A study page is listed here only where we read its question, design and finding and the study was about this condition: its subjects had the condition, or were an animal or cell model of it, and the study gave them the compound. A study that only mentions the condition is not listed.

Studies are grouped by the compound each is filed under and ordered by design: meta-analyses and randomized trials in people first, then other studies in people, then animals, then cells, and within a group by size and then by year. The FDA status comes from the labels our legal-status and brand pages read.